Nordea is hot on Novo Nordisk
A recent announcement from the EMA that the agency discovered no increased risk of cancer from the class of drugs Novo Nordisk’s blockbuster Victoza belongs to will cause a rise in the price of the Danish company’s share, says Nordea.
by Benjamin Werner Christensen
Following a period of heavy debate, the European Medicines Agency (EMA) last Friday offered its support to Victoza and other GLP-1 drugs by ruling out an increased risk of pancreatic cancer from the medicine type. It is welcome news for Novo Nordisk, and it also supports what FDA has said in the matter previously.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
